申请人:Takeda Pharmaceutical Company Limited
公开号:US11230541B2
公开(公告)日:2022-01-25
Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
本发明提供了一种杂环化合物,该化合物可对含有 NR2B 亚基的 NMDA 受体产生拮抗作用,有望用作重度抑郁症、躁郁症、偏头痛、疼痛、痴呆症的外周症状等的预防或治疗药物。由式(I)代表的化合物:
其中各符号如说明书所述,或其盐类。